In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has ... by introducing a gene known as BCL11A which down-regulates the production of the adult form of the oxygen-carrying ...

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Thursday. Other analysts have also issued reports about the stock.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” rating in a research report issued on Friday, Marketbeat ...

About the CRISPR Collaboration and Vertex CRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop ...